Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
- Associated Therapies
- -
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT00824135
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
- Conditions
- Interventions
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 1
- Registration Number
- NCT00801931
- Locations
- 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States
Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00793845
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Haploidentical Stem Cell Transplantation in Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT00790413
- Locations
- 🇸🇪
Lund University Hospital, Department of Pediatric Oncology and Bone Marrow Transplantation, Lund, Sweden
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
- Conditions
- Acute Biphenotypic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaLymphoplasmacytic LymphomaMantle Cell LymphomaMyelodysplastic SyndromeNon-Hodgkin LymphomaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 135
- Registration Number
- NCT00719888
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Autologous Stem Cell Transplantation for Crohn's Disease
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 20
- Registration Number
- NCT00692939
- Locations
- 🇺🇸
UPMC Prebyterian- Adult Gastroenterology, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC-Bone Marrow Team, Pittsburgh, Pennsylvania, United States
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
- Conditions
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyProcedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: MethotrexateDrug: ThiotepaDrug: Vincristine Sulfate
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 70
- Registration Number
- NCT00653068
- Locations
- 🇺🇸
Prisma Health Richland Hospital, Columbia, South Carolina, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Lee Memorial Health System, Fort Myers, Florida, United States
Freiburg ZNS-NHL Study
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2009-11-17
- Lead Sponsor
- University Hospital Freiburg
- Target Recruit Count
- 78
- Registration Number
- NCT00647049
- Locations
- 🇩🇪
University Hospital Freiburg, Freiburg, Germany
MT2004-30: Tomotherapy for Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00623077
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2018-11-26
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT00621036
- Locations
- 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.